|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.50 CHF | -2.02% |
|
-6.32% | -26.62% |
| 17/02 | Newron Pharmaceuticals Plans EUR38 Million Subscription to Fund Schizophrenia Drug Program | MT |
| 17/02 | Newron secures up to 38 million euros to advance phase III evenamide program | RE |
| Capitalization | 402M 466M 363M 347M 633M 42.94B 651M 4.29B 1.71B 20.53B 1.75B 1.71B 73.96B | P/E ratio 2025 * |
-28.9x | P/E ratio 2026 * | -38.6x |
|---|---|---|---|---|---|
| Enterprise value | 425M 492M 384M 367M 669M 45.38B 688M 4.54B 1.81B 21.7B 1.85B 1.81B 78.16B | EV / Sales 2025 * |
21.1x | EV / Sales 2026 * | 15.1x |
| Free-Float |
87.45% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Newron Pharmaceuticals S.p.A.
| 1 day | -2.02% | ||
| 1 week | -6.32% | ||
| Current month | -5.91% | ||
| 1 month | -9.61% | ||
| 3 months | -9.42% | ||
| 6 months | +97.52% | ||
| Current year | -26.62% |
| 1 week | 16.86 |  | 18.7 |
| 1 month | 16.86 | | 21.5 |
| Current year | 16.86 | | 31.85 |
| 1 year | 5.2 | | 31.85 |
| 3 years | 3.7 | | 31.85 |
| 5 years | 1.01 | | 31.85 |
| 10 years | 0.9 | | 31.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 62 | 15/05/2012 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01/01/2012 |
Filippo Moriggia
COO | Chief Operating Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Luca Benatti
BRD | Director/Board Member | 65 | 23/03/2011 |
| Director/Board Member | 80 | 01/01/2008 | |
Stefan Weber
BRD | Director/Board Member | 62 | 15/05/2012 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.02% | -6.32% | +119.30% | +195.61% | 466M | |
| -1.39% | -6.85% | -8.31% | -8.31% | 44.08B | |
| -2.12% | -0.04% | +21.65% | +38.23% | 33.16B | |
| +1.46% | +5.88% | +18.52% | +47.53% | 30.96B | |
| +0.38% | -3.54% | -6.49% | -13.02% | 28.8B | |
| +0.74% | -1.58% | +156.08% | +379.72% | 19.74B | |
| -5.41% | -5.75% | +56.22% | +114.20% | 13.96B | |
| +2.34% | +2.55% | +46.60% | +172.31% | 13.56B | |
| -0.75% | -5.48% | +25.26% | -0.38% | 12.88B | |
| -1.15% | -5.87% | +126.43% | +120.23% | 12.35B | |
| Average | -0.79% | -3.41% | +55.53% | +104.61% | 21B | |
| Weighted average by Cap. | -0.62% | -3.17% | +34.19% | +71.42% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 20.13M 23.3M 18.18M 17.38M 31.69M 2.15B 32.58M 215M 85.65M 1.03B 87.43M 85.59M 3.7B | 29.41M 34.04M 26.55M 25.39M 46.29M 3.14B 47.59M 314M 125M 1.5B 128M 125M 5.41B |
| Net income | -12.86M -14.88M -11.61M -11.1M -20.24M -1.37B -20.81M -137M -54.71M -656M -55.84M -54.67M -2.36B | -10.26M -11.88M -9.26M -8.86M -16.15M -1.1B -16.6M -110M -43.65M -524M -44.56M -43.62M -1.89B |
| Net Debt | 22.84M 26.43M 20.62M 19.72M 35.94M 2.44B 36.95M 244M 97.15M 1.17B 99.17M 97.08M 4.2B | 43.15M 49.94M 38.96M 37.26M 67.91M 4.61B 69.82M 460M 184M 2.2B 187M 183M 7.93B |
Employees
22
Calendar
24/03 -
Earnings release - Annual 2025
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/03/26 | 17.50 CHF | -2.02% | 72,613 |
| 10/03/26 | 17.86 CHF | +1.71% | 56,243 |
| 09/03/26 | 17.56 CHF | -0.45% | 80,190 |
| 06/03/26 | 17.64 CHF | -3.61% | 102,746 |
| 05/03/26 | 18.30 CHF | -2.03% | 68,646 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
19.38EUR
Average target price
51.86EUR
Spread / Average Target
+167.54%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NWRN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition